Skip to main content

Articles

Simponi (Golimumab) Receives New FDA Indication as the First Subcutaneous Anti-TNF Therapy for Ulcerative Colitis

Simponi Aria (Golimumab): A New Intravenous TNF Inhibitor for the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis

Stelara (Ustekinumab) Receives New FDA Indication for the Treatment of Patients with Active Psoriatic Arthritis

Tafinlar (Dabrafenib) and Mekinist (Trametinib): Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations

Tecfidera (Dimethyl Fumarate), a New Oral Therapy Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis

Xiaflex (Collagenase Clostridium Histolyticum), First Drug Approved by the FDA for Peyronie’s Disease

Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases

Conference Highlights ASH

The Single-Agent BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Responses Observed In All Mantle-Cell Lymphoma Patients

Conference Highlights ASH

Rituximab Maintenance Therapy after Autologous Stem-Cell Transplantation Prolongs Progression- Free Survival in Patients with Mantle-Cell Lymphoma

Conference Highlights ASH

Ibrutinib Overcomes Carfilzomib Resistance in Immunoproteasome-Deficient Mantle-Cell Lymphoma

Page 155 of 245
Results 1541 - 1550 of 2441